A recently published study led by Wayne State University on a new approach to understanding chronic inflammation could lead to new advancements in the treatment of many debilitating medical conditions ...

Overall, the median real world time on treatment for earliest olaparib monotherapy 4.6 months (95% CI 3.5 - 5.5), for patients with less than 3 lines of therapy was 5.3 months (95% CI 4.0 – 8.2), and ...

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

Objective Colorectal cancer is primarily treated with surgery. Major surgery and older age are risk factors associated with postoperative decline in cognitive function. In clinical research, a wide ...

Rhode Island ranked second for its lung cancer survival rate, with more than 35% living five years post diagnosis. The state ...

The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.

The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.

Merus said the Food and Drug Administration approved Bizengri, the first treatment for adults diagnosed with pancreatic adenocarcinoma or non-small cell lung cancer that are advanced unresectable or ...

The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, offering a treatment ...

The 66th American Society of Hematology Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...